Valeo Pharma (TSE:VPH) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Valeo Pharma Inc. has revised its credit agreement with Sagard Healthcare Royalty Partners, extending the due date for an initial $10 million payment and reducing its loan principal by approximately C$6.5 million. The amendment offers Valeo Pharma enhanced financial flexibility to pursue its strategic plans. The company focuses on the commercialization of specialty pharmaceuticals in Canada.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.